Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy.

被引：0
|
作者：
Reed, N
Chan, S
Hayward, C
Burger, HU
Huinink, WT
机构：
[1] Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[2] City Hosp Nottingham, Nottingham, England
[3] F Hoffmann La Roche, Basel, Switzerland
[4] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：479S / 479S
页数：1
相关论文
共 50 条
  • [1] Epoetin beta treatment to prevent anemia in solid tumor patients receiving platinum-based chemotherapy.
    Ordóñez, A
    González-Barón, M
    Isla, D
    Sánchez, A
    Arrivi, A
    Manzano, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 785S - 785S
  • [2] Impact of cyclophilin A on survival in gastric cancer patients who received platinum-based chemotherapy.
    Maeng, Chi Hoon
    Baek, Sun Kyung
    Sung, Ji-Youn
    Kim, Si-Young
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin α in anemic cancer patients receiving platinum-based chemotherapy
    Granetto, C
    Ricci, S
    Martoni, A
    Pezzella, G
    Testore, F
    Mattioli, R
    Lampignano, M
    Tacconi, F
    Porrozzi, S
    Gasparini, G
    Mantovani, G
    ONCOLOGY REPORTS, 2003, 10 (05) : 1289 - 1296
  • [4] Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in anemic cancer patients receiving cycling chemotherapy.
    Cheung, WK
    Danneman, B
    Wacholtz, M
    Lau, H
    Miller, D
    BLOOD, 2004, 104 (11) : 111B - 112B
  • [5] Epoetin beta (NeoRecormon®) prevents anaemia and improves quality of life in lung cancer patients receiving platinum-based chemotherapy
    Ordóñez, A
    Gonzalez-Baron, M
    De Castro, J
    Isla, D
    Sanchez, A
    Arrivi, A
    Manzano, J
    LUNG CANCER, 2005, 49 : S339 - S339
  • [6] Early intervention with epoetin-alfa during platinum-based chemotherapy.
    Savonije, J
    Van Groeningen, C
    Van Bochove, A
    Pinedo, H
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 756S - 756S
  • [7] Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy.
    Staley, Stuart-Allison Moffat
    Tucker, Katherine
    Newton, Meredith
    Ertel, Michelle
    Zhang, Yingao
    Doherty, Irene
    Gehrig, Paola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Staley, Stuart-Allison Moffat
    Tucker, Katherine
    Oldan, Jorge
    Moore, Dominic T.
    Newton, Meredith
    Ertel, Michelle
    West, Lindsay
    Bae-Jump, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Once weekly subcutaneous (SC) dosing of epoetin alfa (Procrit) for anemic cancer patients receiving chemotherapy.
    Samuel, J
    Mullai, N
    Mathew, D
    BLOOD, 2000, 96 (11) : 156B - 156B
  • [10] Predicting clinical outcome of Epoetin alfa therapy by tumor type in anemic cancer patients receiving chemotherapy.
    Glaspy, J
    BLOOD, 1996, 88 (10) : 3285 - 3285
12345